Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Timothy L. Zisman"'
1
Akademický článek
The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions
Autor: Stephen M. Vindigni, Timothy L. Zisman, David L. Suskind, Christopher J. Damman
Publikováno v: Therapeutic Advances in Gastroenterology, Vol 9 (2016)
We discuss the tripartite pathophysiological circuit of inflammatory bowel disease (IBD), involving the intestinal microbiota, barrier function, and immune system. Dysfunction in each of these physiological components (dysbiosis, leaky gut, and infla
Externí odkaz: https://doaj.org/article/ca1a5835f173404ea82c6413acf9b1b3
Zobrazit plný text záznamu
2
Akademický článek
Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis.
Autor: Christopher J Damman, Mitchell J Brittnacher, Maria Westerhoff, Hillary S Hayden, Matthew Radey, Kyle R Hager, Sara R Marquis, Samuel I Miller, Timothy L Zisman
Publikováno v: PLoS ONE, Vol 10, Iss 8, p e0133925 (2015)
ObjectiveFecal microbiota transplantation (FMT) is an investigational treatment for diseases thought to involve alterations in the intestinal microbiota including ulcerative colitis (UC). Case reports have described therapeutic benefit of FMT in pati
Externí odkaz: https://doaj.org/article/aa049743716f4c5984bf77ef81fa5d3f
Zobrazit plný text záznamu
3
Obesity and inflammatory bowel disease
Autor: Sophia M Swanson, Timothy L. Zisman, Jason Harper
Publikováno v: Current Opinion in Gastroenterology. 34:112-119
The review summarizes our current understanding of how obesity impacts diagnostic studies and therapies used in inflammatory bowel disease (IBD) as well as the safety and efficacy of medical and surgical weight loss therapies in the obese IBD patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660ae605648b9b5dd507ba2401b3fa08
https://doi.org/10.1097/mog.0000000000000422
Zobrazit plný text záznamu
5
The microbiota in inflammatory bowel disease: current and therapeutic insights
Autor: Erin R. Lane, David L. Suskind, Timothy L. Zisman
Publikováno v: Journal of Inflammation Research
Inflammatory bowel disease is a heterogeneous group of chronic disorders that result from the interaction of the intestinal immune system with the gut microbiome. Until recently, most investigative efforts and therapeutic breakthroughs were centered
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b11a8db94fa3f1a0959a25f7dce17c35
https://doi.org/10.2147/jir.s116088
Zobrazit plný text záznamu
10
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease
Autor: Timothy L. Zisman, Jason Harper, Mika N. Sinanan
Publikováno v: Inflammatory Bowel Diseases. 19:2118-2124
Background Obesity is an emerging problem in the care of inflammatory bowel disease (IBD) patients and has been associated with a diminished response to adalimumab. Whether obesity influences the response to infliximab (IFX) is not known. Methods A r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf8e714590cae1a3b953c7f6a1c9c2b3
https://doi.org/10.1097/mib.0b013e31829cf401
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje